Nucleai Appoints Vikas Ahuja as Vice President of Strategic Partnerships to Enable Diagnostic Deployment and Commercialization at Scale

Vikas Ahuja brings over 20 years of strategic business experience in the life sciences industry from Quest Diagnostics, Ambry Genetics and Mallinckrodt Pharmaceuticals

CHICAGO--(BUSINESS WIRE)--Nucleai, a spatial AI biomarker company that deciphers cellular conversations and maps cellular interactions within tissue samples to predict therapeutic outcomes, announced today the expansion of its executive leadership team with the appointment of Vikas Ahuja as Vice President of Strategic Partnerships. With over 20 years of experience in life sciences, Ahuja will be responsible for building an ecosystem of partners—including diagnostic companies, contract research organizations (CROs), assay and instrument vendors, and software companies—that will enable Nucleai’s AI platform to be deployed at scale for late-stage clinical trials and diagnostic applications.

"Vikas has a wealth of experience and knowledge in business development across various sectors within the life sciences industry and is a perfect addition to our team,” said Avi Veidman, CEO of Nucleai. “Our AI spatial technology is currently used in an active clinical trial to aid patient selection. We’re seeing an increasing need for AI spatial biomarkers to support the rapidly growing pipeline of next-generation treatments, including antibody-drug conjugates, multi-specifics, and novel checkpoint inhibitors. Vikas’ proven track record of fostering strategic alliances and driving global growth initiatives speaks volumes about his expertise in building partnerships to scale the deployment of novel diagnostics. We are thrilled to welcome him to Nucleai, where his insights and leadership will accompany our mission to power the next generation of precision therapeutics with AI-driven spatial biomarkers and diagnostics.”

Before joining Nucleai, Ahuja held a leadership role as Vice President of Business Development & Strategy at Ambry Genetics, where he spearheaded corporate strategy, M&A activities, and licensing initiatives, and oversaw International business segments. He also led the establishment of international partnerships, strategically forging alliances across regions like Latin America, the Middle East, Southeast Asia, China, and Australia at Mallinckrodt Pharmaceuticals.

"This role presents a tremendous opportunity to leverage my experience in building impactful collaborations across the life sciences sector,” said Ahuja. “The recent partnership with GoPath Diagnostics is a prime example of how strategic alliances can advance our mission of transforming patient care through advanced AI-driven spatial biomarkers. I look forward to fostering similar partnerships to enhance our relationships with large commercial and diagnostic companies, propelling our innovative platform to new heights and ultimately improving patient outcomes."

Ahuja earned his MBA from The Wharton School of the University of Pennsylvania and his MS in Chemical Engineering from Imperial College, London.

About Nucleai

Nucleai is the leading AI-powered spatial biomarker company, driving innovation at the intersection of technology and healthcare. Leveraging military intelligence-grade geospatial analytical methods, it intercepts, interprets, and analyzes complex cellular conversations and spatially oriented interactions within tissue samples, translating them into actionable insights. Nucleai’s platform empowers pathologists and researchers with an AI-powered data-rich action plan, paving the way for more informed decisions in the development of bi-specifics, antibody-drug conjugates (ADCs), and immunotherapy. Nucleai's investors include Section 32, Sanofi, Vertex Ventures, M Ventures, and Debiopharm Innovation Fund. It is headquartered in Israel and Chicago. For more information, please visit www.nucleai.ai.